Over the next six months, Morgans expects catalysts to de-risk the regulatory pathway and build upon a strong business case for global pharma interest.
The third quarter cash flow report showed Morgans there’s sufficient cash to see out a number of these catalysts in the short term. The Speculative Buy and $0.38 target price are maintained.
Sector: Pharmaceuticals, Biotechnology & Life Sciences.
Target price is $0.38.Current Price is $0.21. Difference: $0.17 – (brackets indicate current price is over target). If ANP meets the Morgans target it will return approximately 81% (excluding dividends, fees and charges – negative figures indicate an expected loss).
